Prediction of lung failure at COVID-19-Ill
While many infections with novel Coronavirus SARS-CoV-2 to be harmless or even without symptoms, however, some of the Infected it comes to severe disease. These patients often have severe lung damage. Researchers from Munich are now reporting on a Marker for the prediction of severe COVID-19-gradients.
Doctors of the hospital of the University of Munich (LMU) were able to show in a pilot study, that the messenger substance, Interleukin-6 is increased in patients with severe COVID-19 gradients, and the blood level is the need to intensively stay a high probability of early detection.
COVID-19 disease takes a very different course
The COVID-19 disease can take for the patients, a very different course.
According to a recent notification by the hospital is for doctors to be very helpful to identify early on which COVID-19-patients and in -patients, respiratory failure is imminent.
These Patients could then be monitored intensively. In return, patients can be without the risk characteristics of the normal station or even treated at home.
Thus, places can be spared in intensive care units and those Diseased will be assigned to you really need.
In one study, researchers at the LMU clinic in Munich have now found the so-called biomarkers, which allow exactly this distinction. The results were recently published in the “Journal of Allergy and Clinical Immunology”.
Impending Overloading of the capacity of the intensive care units
Most of the people develop after an infection with the Coronavirus SARS-CoV-2 only easily and recover quickly. In about five percent of Patients but when it comes to a severe Disease process with respiratory distress.
Some of these patients have to be ventilated on the intensive care artificial. In the case of a fast rising number of infections, the capacity of the intensive care units could be overloaded.
“We saw in March and April, many patients with COVID-19 decide in our emergency room and had to anticipate which of the patients with a severe course of the disease,” explained PD Dr. med. Tobias Herold and Dr. med. Tobias Weinberger, senior physicians of Central emergency Department (ZNA) at the Campus Großhadern of the LMU hospital.
In order to detect Diseased, which is a deterioration in the condition threatens, “we need markers to tell the clinical course of this previously”.
Prediction with high accuracy
Together with colleagues from the LMU hospital, PD Dr. Tobias Herold, Dr. Tobias Weinberger examined in a pilot study the clinical course and laboratory parameters of 89 COVID-19-Patients had to be treated due to the Severity of the disease in the hospital.
Of this group, 32 people had to be ventilated – mostly men – artificial.
It turned out that all of these patients increased levels of a Marker for inflammation, IL-6, and showed in the blood. Even more: “An IL-6 value of more than 80 picogram/Milliliter, and a CRP value of more than 9.7 milligrams/deciliter during the disease and later lung ahead of failure with a high degree of accuracy, said,” explains Dr. Tobias Herold.
The risk of pulmonary failure was increased for patients with elevated values many times over.
Medicines could affect the disease course, possibly positive
International is a great need for such findings, and the scientific interest is currently large.
According to the experts is still unclear whether IL-6 is a key factor of the escalating disease process in the lung, or merely a Marker of disease activity.
If the former is true, could drugs that intervene in these inflammatory processes influence the disease course positively. To address this question is currently being carried out also at the LMU hospital of the COVACTA study. This attempts to limit the excessive inflammatory process. (ad)
